Nephros, Inc.

{
  "main_header": {
    "sid": 1158034,
    "name": "Nephros, Inc.",
    "stock_name": "Nephros, Inc.",
    "full_name": "Nephros, Inc.",
    "name_url": "stocks-analysis/nephros-inc",
    "exchange": 1,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "3.87",
    "chg": 0.06,
    "chgp": "1.57%",
    "dir": 1,
    "prev_price": "3.81",
    "mcapval": "48.46",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2325,
    "indexname": "S&P 500",
    "isin": "US6406714005",
    "curr_date": "Feb 06",
    "curr_time": "",
    "bse_nse_vol": "55.59 k",
    "exc_status": "Active",
    "traded_date": "Feb 06, 2026",
    "traded_date_str": "2026 02 06",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/nephros-inc-1158034-1&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Is Nephros, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-nephros-inc-overvalued-or-undervalued-3689263",
        "imagepath": "",
        "date": "2025-11-11 11:33:25",
        "description": "As of 7 November 2025, the valuation grade for Nephros, Inc. moved from attractive to very attractive, indicating a stronger outlook for the company. The stock is currently considered undervalued, with a P/E ratio of 36, a Price to Book Value of 3.83, and an EV to EBITDA of 31.89. In comparison to peers, Nephros has a PEG ratio of 0.23, while Nutriband, Inc. shows a negative P/E of -11.62, highlighting Nephros's relative strength in valuation metrics.\n\nDespite the lack of recent return data, Nephros's valuation ratios suggest it is positioned favorably within the Pharmaceuticals & Biotechnology sector. The company's ROCE of 13.86% and ROE of 8.62% further support its attractiveness in the market...."
      }
    ],
    "total": 8,
    "sid": "1158034",
    "stock_news_url": "https://www.marketsmojo.com/news/nephros-inc-1158034"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Is Nephros, Inc. overvalued or undervalued?

2025-11-11 11:33:25

As of 7 November 2025, the valuation grade for Nephros, Inc. moved from attractive to very attractive, indicating a stronger outlook for the company. The stock is currently considered undervalued, with a P/E ratio of 36, a Price to Book Value of 3.83, and an EV to EBITDA of 31.89. In comparison to peers, Nephros has a PEG ratio of 0.23, while Nutriband, Inc. shows a negative P/E of -11.62, highlighting Nephros's relative strength in valuation metrics. Despite the lack of recent return data, Nephros's valuation ratios suggest it is positioned favorably within the Pharmaceuticals & Biotechnology sector. The company's ROCE of 13.86% and ROE of 8.62% further support its attractiveness in the market....

Read full news article

View All News